KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $62.4 million.

  • Supernus Pharmaceuticals' Other Non-Current Assets changed N/A to $62.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.4 million, marking a year-over-year change of. This contributed to the annual value of $31.5 million for FY2024, which is 1593.92% down from last year.
  • Supernus Pharmaceuticals' Other Non-Current Assets amounted to $62.4 million in Q3 2025.
  • Supernus Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $403.8 million during Q1 2023, with a 5-year trough of $28.0 million in Q2 2025.
  • Moreover, its 5-year median value for Other Non-Current Assets was $39.3 million (2022), whereas its average is $60.1 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other Non-Current Assets skyrocketed by 552397.77% in 2021, and later tumbled by 9049.85% in 2024.
  • Supernus Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $49.2 million in 2021, then fell by 19.15% to $39.8 million in 2022, then decreased by 5.78% to $37.5 million in 2023, then dropped by 15.94% to $31.5 million in 2024, then skyrocketed by 98.03% to $62.4 million in 2025.
  • Its Other Non-Current Assets stands at $62.4 million for Q3 2025, versus $28.0 million for Q2 2025 and $29.2 million for Q1 2025.